Lavior Pharma Inc published the RENEW Study in the Journal of Wound Care evaluating Lavior's Diabetic Wound Therapy against SoloSite, a standard hydrogel from Smith+Nephew in a prospective randomized controlled trial.

Lavior® Pharma: Advanced Botanical-Based, Bio-Engineered Solutions for Diabetic Wound and Skincare Lavior® is redefining diabetic wound care through the development of advanced, botanical-based medical devices designed to treat chronic, hard-to-heal wounds and skin conditions. As the only company solely dedicated to the therapeutic skincare needs of the diabetic population, Lavior® delivers clinically proven solutions aimed at improving outcomes and reducing the risk of complications, including amputation. Our proprietary formulations, based on the Inula AGS-RIED botanical species, are engineered using pharmaceutical-grade ingredients and supported by over 15 years of scientific research and clinical trials. Lavior® products are FDA-compliant and manufactured to the highest safety and efficacy standards, consistently outperforming conventional treatments in clinical settings. Indicated for diabetic foot ulcers, pressure injuries, burns, eczema, fungal and bacterial infections, and other dermatological complications, the Lavior® product line is designed to integrate seamlessly into wound care protocols across outpatient, inpatient, and home care environments. Lavior® is committed to advancing wound care with innovative medical solutions that help clinicians improve healing, prevent amputations, and elevate patient quality of life.